USC.edu
Are You a Patient?

Lee Ann Baxter-Lowe, PhD

Professor Of Clinical Pathology

Image of Lee Ann Baxter-Lowe, PhD
Is this your profile? Click to edit
Phone +1 323 361 5279
Email [email protected]
CTSI Profile

Overview

Dr Baxter-Lowe’s research involves characterizing HLA polymorphism and determining its relevance in transplantation and human disease. In recent years she has been investigating the role of HLA antibodies in transplantation of solid organs and hematopoietic stem cells. Her laboratory has supported numerous single and multicenter clinical trials in transplantation and has been a core laboratory for the NIH Immune Tolerance Network. Her research has been reported in more than 125 scientific publications.

Dr. Baxter-Lowe has also served as a clinical histocompatibility laboratory director and in this capacity has been involved in advancing histocompatibility testing and its clinical application. She has had a long-standing commitment to policy development and is currently serving as Chair of the Histocompatibility Committee of the United Network for Organ Sharing (UNOS) and is the facilitator for the Histocompatibility Workgroup for the 2012 National Consensus Conference on Kidney Paired Donation (KPD). She has served as a member or chair of numerous national and international committees in this field.

Publications

  • Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation. Bone Marrow Transplant. 2021 09; 56(9):2221-2230.. View in PubMed
  • Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 07; 27(7):591-599.. View in PubMed
  • The discovery of the HLA-B*56:75 allele shows that HLA sequencing is important in all transplant settings. HLA. 2021 05; 97(5):463-464.. View in PubMed
  • Growing evidence that 2-field high-resolution HLA typing is important for kidney transplantation. Am J Transplant. 2020 12; 20(12):3277-3278.. View in PubMed
  • Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant. Biol Blood Marrow Transplant. 2020 10; 26(10):1930-1936.. View in PubMed
  • The clinical impact of donor-specific antibodies on antibody-mediated rejection and long-term prognosis after heart transplantation. Curr Opin Organ Transplant. 2019 06; 24(3):245-251.. View in PubMed
  • The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia. Bone Marrow Transplant. 2019 02; 54(2):226-235.. View in PubMed
  • Human leukocyte antigens antibodies after lung transplantation: Primary results of the HALT study. Am J Transplant. 2018 09; 18(9):2285-2294.. View in PubMed
  • CPRA for allocation of kidneys in the US: More candidates ≥98% CPRA, lower positive crossmatch rates and improved transplant rates for sensitized patients. Hum Immunol. 2016 May; 77(5):395-402.. View in PubMed
  • A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2016 Apr; 22(4):698-704.. View in PubMed

Similar People